Allogeneic transplantation using peripheral blood stem cells

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 4, 2001, Pages 685-700

  Russell, N H ^a,b   Byrne, J L ^a,b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Allogeneic transplantation; Graft versus host disease; Leukaemia; Peripheral blood stem cells; Unrelated donors

Indexed keywords

ALEMTUZUMAB; CD34 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CYCLOSPORIN; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; INTERLEUKIN 4; METHOTREXATE; PREDNISOLONE; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY;

ADVANCED CANCER; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; BONE PAIN; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EUROPE; FATIGUE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; LEUKEMIA; LIVING DONOR; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MORTALITY; NAUSEA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIBLING; SICKLE CELL CRISIS; SPLEEN RUPTURE; STEM CELL MOBILIZATION; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; BLOOD CELL; HISTOCOMPATIBILITY; IMMUNOLOGY; METHODOLOGY; REVIEW; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

BLOOD CELLS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKEMIA; STEM CELL TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035544309     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0167     Document Type: Article

References (68)

1. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers
2. G-CSF-mobilised peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilisation, and composition of graft
3. The place of blood stem cells in allogeneic transplantation
4. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood stem cell mobilisation in healthy donors
5. + immunoselection
6. A randomised comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilisation in healthy donors for allogeneic transplantation
7. A comparative study of once daily versus twice daily filgrastim administration for the mobilisation and collection of CD34+ peripheral blood progenitor cells in normal donors
8. Collection of peripheral blood stem cells from normal donors 60 years of age or older
9. Donor age-related differences in PBPC mobilisation with rHu-G-CSF
10. Allogeneic blood stem cell transplantation: Considerations for donors
11. Treatment of normal individuals with granulocyte-colony-stimulating factor: Donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells
12. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors
13. Experiences of donors enrolled in a randomised study of allogeneic or peripheral blood stem cell transplantation
14. Spontaneous splenic rupture following administration of granulocyte-colony-stimulating factor (G-CSF) occurring in an allogeneic donor of peripheral blood stem cells
15. Spontaneous rupture of spleen during peripheral blood stem cell mobilisation in a healthy donor
16. Spleen enlargement in healthy donors during G-CSF mobilisation of PBPCs
17. Unusual adverse events following peripheral blood stem cell mobilisation using granulocyte colony stimulating factor (G-CSF) in healthy donors
18. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration
19. Peripheral blood stem cell (PBSC) donation: An analysis from the International Bone Marrow Transplant registry and the European Group for Blood and Marrow transplant (EBMT) databases
20. Effects of short term administration of G-CSF (filgrastim) on bone marrow progenitor cells: Analysis of serial marrow samples from normal donors
21. Blood counts in healthy donors I year after collection of granulocyte-colony-stimulating-factor-mobilised progenitor cells and the results of a second mobilisation and collection
22. Three to six year follow up of normal donors who received recombinant human granulocyte colony stimulating factor
23. Allogeneic peripheral blood stem cell transplantation for haematological malignancies-an analysis of engraftment and GVHD risk
24. Allogeneic bone marrow transplantation versus filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia; first results of a randomised multicentre trial of the and Marrow Tansplantation
25. Chronic graft versus host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study
26. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft versus host disease
27. Pre-treatment of donor mice with granulocyte colony-stimulating factor polarizes donor T-lymphocytes towards Type-2 cytokine production and reduces severity of experimental graft versus host disease
28. Granulocyte-colony stimulating factor mobilises T helper 2-inducing dendritic cells
29. Peripheral-blood stem-cells as an alternative to marrow for allogeneic transplantation
30. Allogeneic granulocyte colony-stimulating factor mobilised peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation
31. Primary Transplantation of allogeneic peripheral-blood progenitor cells mobilized by filgrastim (granulocyte-colony-stimulating factor)
32. Transplantation of allogeneic peripheral blood stem cells mobilised by recombinant human granulocyte colony-stimulating factor
33. Allogeneic blood stem cell transplantation for refractory leukaemia and lymphoma: Potential advantages of blood over marrow allograft
34. A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic and marrow transplantation of filgrstim-mobilised peripheral blood progenitor cells with bone marrow 350 patients with leukaemia
35. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
36. Improved reconstitution of CD4 cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow
37. Allogeneic blood and bone marrow stem cell transplantation in haematological malignant disease: A randomised trial
38. + selected grafts with recipients of unmanipulated grafts
39. Randomised trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukaemia: A report from the Société Française de Greffe de Moelle
40. Transplantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with haematologic cancers
41. A Canadian randomised study comparing peripheral blood and bone marrow in patients undergoing matched sibling transplants for myeloid malignancies
42. Blood stem cells compared with bone marrow as a source of haemopoietic cells for allogeneic transplantation
43. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow
44. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
45. Acute graft versus host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate
46. Clinical outcome in 112 patients following HLA-identical allogeneic peripheral blood stem cell transplantation
47. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation
48. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with haematological malignancies
49. Long-term follow up of high risk allogeneic peripheral blood stem cell transplant recipients: Graft versus host disease and transplant-related mortality
50. An analysis of the effect of chronic GVHD on relapse and survival following allogeneic PBSC transplantation
51. The risk of residual molecular and cytogenetic disease in patients with Philadelphia chromosome positive first chronic phase chronic myelogenous compared with bone marrow
52. Progress in allogeneic bone marrow and peripheral blood transplantation for multiple myeloma: A comparison between transplants performed 1983-1993 and 1994-1998 at European Group for Blood and Marrow Transplantation Centres
53. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of haemopoietic cells
54. T cell depletion of HLA-identical transplants in leukemia
55. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced haematological malignancy
56. + cells from peripheral blood: Experience of 62 cases using immunoadsorption or immunomagnetic technique
57. + selected cells from peripheral blood from HLA-identical siblings
58. CD34(+) cell dose predicts survival, post-transplant morbidity and rate of haematological recovery after marrow transplants for haematological malignancy
59. Control of graft versus host disease and graft rejection by T cell depletion of donor and recipient with Campath-I antibodies. Results of matched sibling transplants for malignant diseases
60. T cell depletion by exposure to Campath-IG in vitro prevents graft versus host disease
61. CD52 antibodies for prevention of graft versus host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
62. In vivo CAMPATH-IH prevents graft versus host disease following non-myeloablative stem cell transplantation
63. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: An effective regimen with low procedure related toxicity
64. Consensus conference on unrelated donor bone marrow transplantation: Royal College of Physicians of Edinburgh, October 29th and 30th, 1996
65. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukaemia: The effect of leukaemic burden, donor HLA-matching and marrow cell dose
66. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft versus host disease and outcome following unrelated donor transplantation for leukaemia
67. Comparison of unrelated peripheral blood stem cell transplantation with unrelated bone marrow transplantation
68. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation